Meeting Scheduled By HHS To Focus On The Use Of Synthetic Opioids In Drug Testing

About 4 min

Meeting Scheduled By HHS To Focus On The Use Of Synthetic Opioids In Drug Testing

HydrocodoneThe Department of Health and Human Services (HHS) announced this week that a meeting will be held on January 31st 2012 from 9 AM to 3PM EST to focus on the use of Synthetic Opioids.  This public meeting will discuss the science of synthetic opioids as potential analytes (chemicals to be tested within an analytical procedure) to be included in the mandatory guidelines for Federal Workplace Drug Testing Programs.

Background Information
On October 1, 2011, the Department of Transportation (DOT) enhanced the DOT drug testing panel configuration adding analytes to two panels; Amphetamines and Opiates. With the enhancement of MDMA/MDA/MDEA, commonly known as Ecstasy, to the Amphetamine panel and added additional requirements when testing 6-AM (heroin) under the Opiate panel, the DOT is holding a meeting to discuss alternative synthetic opioids not being tested today under the federal regulations. 

The Opioid family contains many different synthetic opioids. Not all synthetic opioids are tested under the “standard” opiate panel at a laboratory for both DOT and Non-DOT purposes.   One can request testing additional synthetic opiates for Non-DOT drug testing such as, codeine, morphone, hydromorphone, hydrocodone, OxyContin and Oxycodone, commonly referred to as the Expanded Opiate panel. Other examples of synthetic opioids that can be ordered include Meperidine and Fentanyl for Non-DOT use.  It is also a common request for Non-DOT companies to update their current 5 panel configuration to the newly enhanced DOT-Like 5 panel.  Please ensure that all regulations and company policies for Non-DOT purposes are met when selecting your panel configuration for testing. 

Registration and Additional Information
For additional information you can go directly to the United States GPO website and reference the volume of the Federal Register  directly.  The meeting is being hosted by the Drug Testing Advisory Board and will take place at the Sugarloaf Conference Room, One Choke Cherry Road, Rockville, MD  20850 or you can attend via teleconference.  This meeting is open to the public and interested parties can register at the SAMHSA Website.  You must register by using this link as limited seating is available.  In addition, a conference call number and access code will be available for interested parties that cannot attend in person.

Employment Background Investigations works with employers to customized drug testing that is compliant, comprehensive and cost effective.  EBI offers a wide variety of options when it comes to drug and alcohol testing programs, from pre-employment, random, post-accident and mobile collection options for both regulated DOT and traditional testing.  With vast expertise and knowledge, EBI can help you develop a drug testing program to meet your specific needs, whether lab based or instant solution. 

EBI is committed to providing employers with valuable education and resources on changing legislation and cutting-edge and compliant solutions to meet federal, state, local and international mandatory requirements. All content provided by EBI is published for the convenience of its readers and should never be deemed as legal guidance or advice.  Always consult your legal counsel for specific advice on local laws and industry regulations.

If you found this information useful, select the button listed below and access more industry news, resources and tips from EBI, an NAPBS Accredited screening firm and global leader in the background screening industry.

Stay up-to-date on Employment Laws & Regulations with EBI's Screening News Network.